Table 3.
Treatments associated with BIOs, described at the baseline and at the last assessment
| Regional treatment with glucocorticoids preceding baseline, N patients (%) | Peribulbar injection 2 (4.3) |
| Subconjunctival injection 1 (2.1) | |
| Local treatment with steroid drops at the start of BIOs, N eyes (%) | 5 (10.7) |
| Local treatment with steroid drops at the last assessment, N eyes (%) | 4 (8.5) |
| Concomitant GC treatment at the start of BIOs, N patients (%) | 25 (53.2) |
| Concomitant GC treatment at the last assessment, N patients (%) | 12 (15.6) |
| Median GC dose at the start of BIOs (prednisone or equivalent), mg/kg/day (median (IQR)) | 0,1 (0.7) |
| Median GC dose at the last assessment (prednisone or equivalent), mg/kg/day (median (IQR)) | 0 (0) |
| Concomitant cDMARDs at the start of BIOs, N patients (%) | MTX, 21 (44.7) |
| CYC, 4 (8.5) | |
| AZA, 4 (8.5) | |
| MYC, 1 (2.1) | |
| COL, 1(2.1) | |
| Unknown, 3 (6.4) | |
| Concomitant cDMARDs at the last assessment, N patients (%) | MTX, 18 (38.3) |
| CYC, 2 (4.3) | |
| AZA, 2 (4.3) | |
| Unknown, 1 (2,1) |
AZA azathioprine, BIOs biosimilar agent drug, cDMARDs conventional disease-modifying antirheumatic drug, COL colchicine, CYC cyclosporine, GC glucocorticoids, IQR interquartile range, MTX methotrexate, MYC mycophenolate mofetil, N number of patients, Unknown missing value